Signaling Through the Type 2 Cannabinoid Receptor Regulates the Severity of Acute and Chronic Graft versus Host Disease

Authors: Cheng Yin Yuan, Vivian Zhou, Garrett Sauber, Todd M Stollenwerk, Richard Komorowski, Alicia López, Rosa Maria Tolon, Julian Romero, Cecilia J Hillard, William R Drobyski Published in Blood  October…

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.

Authors: Moshe Yeshurun, Ofer Shpilberg, Corina Herscovici, Liat Shargian, Juliet Dreyer, et al
Biology of Blood and Marrow Transplantation, October 2015

Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic cell transplantation (alloHCT). Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent anti-inflammatory and immunosuppressive properties. We hypothesized…

Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: evidence from an experimental murine model.

Authors: Rupal Pandey, Venkatesh L. Hegde, Mitzi Nagarkatti, Prakash S. Nagarkatti
Journal of Pharmacology and Experimental Therapeutics, September 2011

Allogeneic hematopoietic cell transplantation (HCT) is widely used to treat patients with life-threatening malignant and nonmalignant hematological diseases. However, allogeneic HCT often is accompanied by severe and lethal complications from graft-versus-host disease (GVHD)…